Latest 10-K annual reports

SolarEdge Technologies, Inc. significantly improved its financial performance in 2025, reporting a 31.4% revenue increase and a return to gross profitability after a substantial loss in 2024, despite ongoing net losses and legal challenges.

Context Therapeutics Inc. reported a net loss of $36.1 million for 2025 as it advanced its bispecific antibody pipeline for solid tumors, with key clinical trial data expected in 2026.

Bionano Genomics reported a significant reduction in net losses for 2025, driven by cost-saving initiatives, but faces ongoing substantial doubt about its ability to continue as a going concern without further capital.

ParkerVision, Inc. reported significant losses and negative cash flows for fiscal year 2025, raising substantial doubt about its ability to continue as a going concern, as it continues to rely heavily on patent enforcement litigation for future revenue.

Yunhong Green CTI Ltd. reported a 10% increase in net sales to $19.7 million for fiscal year 2025, despite incurring a net loss of $2.53 million and facing going concern doubts.

Semtech Corporation reported a 15% revenue increase to $1.05 billion in fiscal year 2026, driven by infrastructure and industrial markets, despite a net loss and significant goodwill impairment.

Talphera, Inc. reported a net loss of $14.3 million for 2025, raising substantial doubt about its ability to continue as a going concern, despite focusing resources on its lead product candidate, Niyad.

TGE Value Creative Solutions Corp, a blank check company, outlines its securities, governance, and search for a business combination in its latest annual report.

Ultralife Corporation reported a net loss of $5.9 million for 2025, driven by a significant non-cash intangible asset impairment from a global rebranding initiative, despite robust revenue growth and record backlog in its Battery & Energy Products segment.

Ambarella, a leader in AI and computer vision SoCs, reported a 37.2% revenue increase in fiscal year 2026, driven by high demand for its edge AI solutions, despite a net loss.

Procaccianti Hotel REIT, Inc. reports a slight increase in total revenues for 2025, driven by ADR growth in some properties, alongside a decrease in net income and significant unfulfilled share repurchase requests.

The Cannaisseur Group, Inc. reported a 100% revenue decline and significant net losses for fiscal year 2025, transitioning to an online-only sales model while facing substantial doubt about its ability to continue as a going concern.

Richmond Mutual Bancorporation reported a 23.5% increase in net income to $11.6 million for 2025, driven by higher net interest income, while also announcing a definitive merger agreement with The Farmers Bancorp.

EQUATOR Beverage Company reported a significant turnaround in 2025, achieving 29% revenue growth and positive net income after a prior-year loss, driven by improved operating leverage and distribution.

Envoy Medical, Inc. reported a significant net loss and accumulated deficit for fiscal year 2025, raising substantial doubt about its ability to continue as a going concern, despite fully enrolling its pivotal clinical trial for the Acclaim CI.

MAIA Biotechnology reports significant clinical progress for its lead cancer drug ateganosine, initiates Phase 3 trials, and strengthens its financial position with recent capital raises, despite ongoing net losses.

Bally's Corporation reported a significant net loss of $716.5 million in 2025 despite aggressive global expansion and strategic acquisitions, alongside identifying a material weakness in internal controls.

Theravance Biopharma announced the wind-down of its ampreloxetine program following Phase 3 study failure, accelerating a strategic review while focusing on YUPELRI's continued sales growth and cost-cutting restructuring.

Abundia Global Impact Group, Inc. reported a significant increase in net losses for 2025 as it transitions to a low-carbon energy solutions company, despite securing substantial new financing.

Newbridge Acquisition Limited, a blank check company, details its recent $57.5 million IPO, strategy to acquire high-growth companies, and significant risks tied to its China-based management and potential target markets in its latest annual report.

Solo Brands, Inc. reported a significant decline in net sales and continued net losses for fiscal year 2025, raising substantial doubt about its ability to continue as a going concern.

Xilio Therapeutics, a clinical-stage biotechnology company, reported a significant reduction in net losses for 2025, driven by increased collaboration revenue and strategic advancements in its immuno-oncology pipeline.

Cabaletta Bio progresses its lead CAR T therapy, rese-cel, into registrational trials for autoimmune diseases while reporting significant losses and a need for further funding.

Arbutus Biopharma reports a significant patent settlement with Moderna for $950M noncontingent payment, while advancing its HBV pipeline and undergoing substantial corporate restructuring.

Pyxis Oncology announced positive preliminary Phase 1 data for its lead oncology candidate MICVO in HNSCC, both as monotherapy and in combination with KEYTRUDA, but reported significant losses and substantial doubt about its ability to continue as a going concern.

Avalo Therapeutics reported a significant increase in net loss for 2025, driven by higher R&D and administrative expenses, as it progresses its lead drug candidate, abdakibart, towards a critical Phase 2 data readout in Q2 2026.

Idaho Strategic Resources achieved significant financial growth and operational milestones in 2025, driven by increased gold production and strategic advancements in its rare earth element projects.

Core Laboratories Inc. reported a slight revenue increase in 2025, driven by service growth, but saw declines in net income and product sales amidst geopolitical conflicts and a challenging international exploration environment.

Aterian, Inc. reported significantly increased net losses and negative operating cash flow for 2025, prompting a strategic alternatives review and raising substantial doubt about its ability to continue as a going concern.

Wellgistics Health reported a significant net loss of $101.3 million for 2025, facing Nasdaq delisting concerns and substantial debt obligations.